Renal function: Defining long-term success

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 6, 2004, Pages

  Pascual, Julio ^a   Marcén, Roberto ^a   Ortuño, Joaquín ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Calcineurin inhibitor elimination; Chronic allograft nephropathy; Graft survival; Rejection; Renal function; Tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL STUDY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MICROEMULSION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; REGISTER; UNITED STATES;

CALCINEURIN; CHRONIC DISEASE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 11244272877     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1062     Document Type: Article

References (20)

1. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318
2. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003; 349: 2288-2290
3. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590
4. Fitzsimmons WE, Thompson D, Hariharan S, Van Veldhuisen P. Serum creatinine as a surrogate endpoint for graft loss in kidney transplantation: validation efforts from multicenter trials. Am J Transplant 2002; 2 [Suppl 3]: S272 [abstract 533]
5. Jurewicz WA. Tacrolimus versus ciclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 [Suppl 1]: i7-i11
6. Mayer AD for the European Tacrolimus Multicentre Renal Study Group. Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34: 1491-1492
7. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782
8. Kraemer BK, Montagnino G, Arias M, Pascual J, the Tacrolimus vs cyclosporin Follow-up Study Group. Tacrolimus vs cyclosporin microemulsion: 3-year follow-up of a large, multicentre trial. Am J Transplant 2003; 3 [Suppl 5]: S464 [abstract 1220]
9. Gonwa T, Johnson C, Ahsan N et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048-2053
10. Pascual J, Segoloni G, Gonzalez Molina M et al. Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: results of a European trial with 3-year follow up. Transplant Proc 2003; 35: 1701-1703
11. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP for the Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-1567
12. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786
13. Abramowicz D, Manas D, Lao M et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725-1734
14. Grinyo JM, Campistol JM, García J et al. Sirolimus (SIR) and tacrolimus (FK) in renal transplant: results of a randomized trial of a maintenance therapy based in sirolimus versus the combination of sirolimus and tacrolimus. Am J Transplant 2003; 3 [Suppl 5]: 474 [abstract 1256]
15. Rostaing L, Catarovich D, Mourad G, Neumayer H.-H, Rigotti P, the CARMEN Study Group. Steroid-free immunosuppression with a combination of daclizumab, tacrolimus and MMF is efficacious and safe: results of a large multicenter trial in renal transplantation. Am J Transplant 2003; 3 [Suppl 5]: 312 [abstract 627]
16. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841
17. Pascual J, Vanrenterghem Y, van Hooff JP, Squifflet J.-P, Salmela K, Rigotti P. Safe withdrawal of MMF or steroids following 3 months of tacrolimus triple therapy: results of a large, prospective, multicentre study. Transplantation 2002; 74 [Suppl]: 427 [abstract 2105]
18. Gonwa T, Mendez R, Yang HC, for the Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75: 1213-1220
19. Gill JS, Tonelli M, Mix CH, Pereira BJG. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1636-1642
20. Gill JS, Tonelli M, Mix CH, Johnson N, Pereira BJG. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 2004; 65: 692-699